These results suggest that dual blocking of IL-6R and IL-17A could more broadly suppress the gene expressions of molecules elevated in SSc patients at high risk of PAH when compared to strategies involving the inhibition of each cytokine individually. The gene discussed is IL17A; the disease is pulmonary arterial hypertension.